Tao Synergies Inc (TAOX)

$4.57 +0.49 (12.01%)
Market Cap 27.69M
Revenue (ttm) 300,000.00
Net Income (ttm) -28.74M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9,580.00%
Debt to Equity Ratio 0.00
Volume 780,900
Avg Vol 110,024
Day's Range N/A - N/A
Shares Out 7.48M
Stochastic %K 73%
Beta 1.49
Analysts Strong Buy
Price Target N/A

Company Profile

TAO Synergies Inc. owns and operates an AI token. It focuses on the pure play artificial intelligence (AI) crypto coin, TAO, the native cryptocurrency of Bittensor and a decentralized blockchain network for machine learning and AI. The company was formerly known as Synaptogenix, Inc. and changed its name to TAO Synergies Inc. in June 2025. TAO Synergies Inc was incorporated in 2012 and is headquartered in New York, New York.

Industry: Capital Markets
Sector: Financial Services
Phone: 973 242 0005
Address:
1185 Avenue of the Americas, 3rd Floor, New York, United States
EndGame1
EndGame1 Sep. 18 at 2:55 PM
$TAOX Patience paid off. I'm getting close to break even. $5 this month. Bittensor TAO Price #37 rank $252.63 29.4% (1month) "Bittensor saw an 8% price increase following the launch of Subnet 68 (NOVA) for 'Agency Therapeutics' discovery. Increased community engagement and social bullishness also contributed to the upward momentum."
0 · Reply
show_me_the_money_Adam
show_me_the_money_Adam Sep. 18 at 2:03 PM
$TAOX a nice day for crypto!
0 · Reply
EndGame1
EndGame1 Sep. 17 at 3:51 PM
$TAOX We survived that dip. Good days coming. "Bittensor (TAO) rose 3.5% as ORO subnet's Y Combinator acceptance spurred ecosystem development. New cross-chain swaps and app integrations further boosted utility and liquidity, driving positive market sentiment."
0 · Reply
EndGame1
EndGame1 Sep. 14 at 6:15 PM
$TAOX Listening to "This week in Startups" with Jason Calacanis and the founder of $TAO.X explain Bittensor.
0 · Reply
SnoopyPotter
SnoopyPotter Sep. 14 at 5:35 PM
$TAOX Mark Jeffrey is at the All-In Summit with Jason Calacanis and the heavy hitters. Having a Bittensor Fund partner in the room with the people who allocate billions to AI is huge for $TAO.X. This is exactly where decentralized compute needs to be heard. Mindshare + capital conversations in one building. $TAO.X​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​
0 · Reply
EndGame1
EndGame1 Sep. 14 at 4:14 PM
$TAOX Price is flat, but demand is rising. #39 on coin gecko https://www.coingecko.com/en/coins/bittensor?chart=type%3Dprice%26mode%3Dline%26timeframe%3Dd30
0 · Reply
EndGame1
EndGame1 Sep. 8 at 2:53 PM
$TAOX What a Monday. Bittensor $257.30 5.2% bittensor (TAO) 7d chart "Bittensor Surges 25% to $277 on Raydium Listing and Short Squeeze Bittensor's price rose 25% to $277 following its listing on Raydium, strong demand for "Buttensor" trading pairs, and a short squeeze triggered by a concentrated 79% short liquidation position. Protocol upgrades and increased social engagement further supported the rally."
0 · Reply
EndGame1
EndGame1 Sep. 8 at 1:36 PM
$TAOX Should be $5/share. Bittensor is finally found.
0 · Reply
SnoopyPotter
SnoopyPotter Sep. 8 at 12:38 PM
$TAOX I bought some buttensor. as abe experiment - Crashed 75% - gain about $1 in Tao a day off $140 investment - Expecting some more volatility -
1 · Reply
SnoopyPotter
SnoopyPotter Sep. 7 at 2:00 AM
$TAOX Buttensor tao as explained by mark jeffrey : So this morning a 'Bittensor memecoin' appeared on Solana called 'Buttensor' (har har). It was launched in a Raydium pool opposite $TAO.X on Solana. Hold $BUTT.X and you earn $TAO.X. This drives both $BUTT.X and $TAO.X price -- and (important) ALL of this drives **new money** on Solana into TAO either directly or obliquely through BUTT. Through your memecoin antics, Solana people, you drive up the price of serious-coin TAO. The stage is now set for these new kind of price dynamics on both Solana AND Robinhood.
0 · Reply
Latest News on TAOX
TAO Synergies appoints Jeffrey as an advisor to the Company

2026-07-08T13:25:42.000Z - 2 months ago

TAO Synergies appoints Jeffrey as an advisor to the Company

TAO Synergies Appoints Bittensor Investor and Author Mark Jeffrey as Advisor

Jul 8, 2026, 9:15 AM EDT - 2 months ago

TAO Synergies Appoints Bittensor Investor and Author Mark Jeffrey as Advisor

TAO Synergies to join the Russell Microcap Index

2026-06-16T13:21:36.000Z - 3 months ago

TAO Synergies to join the Russell Microcap Index

TAO Synergies Set to Join the Russell Microcap® Index as a Leading Public Gateway to Decentralized AI

Jun 16, 2026, 9:15 AM EDT - 3 months ago

TAO Synergies Set to Join the Russell Microcap® Index as a Leading Public Gateway to Decentralized AI

Options Trading Now Available on Tradr's BEX, CSEX, NNEX & SNPXcsex

Nov 18, 2025, 5:15 PM EST - 10 months ago

Options Trading Now Available on Tradr's BEX, CSEX, NNEX & SNPXcsex

BEX CSEX NNEX SNPX

TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation

Nov 18, 2025, 9:15 AM EST - 10 months ago

TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation

Tradr Launches Leveraged ETFs on Bloom Energy, Celestica, NANO Nuclear & Synopsys

Nov 13, 2025, 6:46 AM EST - 10 months ago

Tradr Launches Leveraged ETFs on Bloom Energy, Celestica, NANO Nuclear & Synopsys

BEX CSEX NNEX SNPX

TAO Synergies files to sell 22.3M shares of common stock for holders

2025-11-12T21:22:16.000Z - 10 months ago

TAO Synergies files to sell 22.3M shares of common stock for holders

Tradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and Synopsys

Nov 11, 2025, 11:26 AM EST - 10 months ago

Tradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and Synopsys

BEX CSEX NNEX SNPX

TAO Synergies announces initial $750K investment in Bittensor Subnet Funds

2025-11-04T14:20:39.000Z - 10 months ago

TAO Synergies announces initial $750K investment in Bittensor Subnet Funds

TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds

Nov 4, 2025, 9:15 AM EST - 10 months ago

TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds

TAO Synergies reports total TAO increased to 54,058 tokens

2025-10-20T13:20:22.000Z - 11 months ago

TAO Synergies reports total TAO increased to 54,058 tokens

TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency

Oct 20, 2025, 9:15 AM EDT - 11 months ago

TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency

TAO Synergies announces $11M private placement

2025-10-13T21:15:14.000Z - 11 months ago

TAO Synergies announces $11M private placement

TAO Synergies Announces $11 Million Private Placement

Oct 13, 2025, 5:09 PM EDT - 11 months ago

TAO Synergies Announces $11 Million Private Placement

TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)

Sep 22, 2025, 9:15 AM EDT - 12 months ago

TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)

TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event

Sep 8, 2025, 9:15 AM EDT - 1 year ago

TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event

TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy

Aug 26, 2025, 9:15 AM EDT - 1 year ago

TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy

TAO Synergies files $100M mixed securities shelf

2025-08-14T20:55:13.000Z - 1 year ago

TAO Synergies files $100M mixed securities shelf

TAO Synergies acquires $10M of Bittensor

2025-07-17T13:21:08.000Z - 1 year ago

TAO Synergies acquires $10M of Bittensor

TAO Synergies files to sell 5.04M shares of common stock for holders

2025-07-11T21:05:08.000Z - 1 year ago

TAO Synergies files to sell 5.04M shares of common stock for holders

TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

Jul 1, 2025, 9:15 AM EDT - 1 year ago

TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

Jun 26, 2025, 9:15 AM EDT - 1 year ago

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

Jun 24, 2025, 9:15 AM EDT - 1 year ago

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

Jun 9, 2025, 9:00 AM EDT - 1 year ago

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Dec 20, 2024, 9:15 AM EST - 1 year ago

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Synaptogenix Announces $5.0 Million Financing

Sep 11, 2024, 9:00 AM EDT - 2 years ago

Synaptogenix Announces $5.0 Million Financing

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Jul 18, 2024, 9:00 AM EDT - 2 years ago

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Jun 26, 2024, 9:00 AM EDT - 2 years ago

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

May 7, 2024, 9:00 AM EDT - 2 years ago

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Apr 24, 2024, 9:15 AM EDT - 2 years ago

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Synaptogenix President Daniel L. Alkon, M.D.

Dec 19, 2023, 9:00 AM EST - 2 years ago

Synaptogenix President Daniel L. Alkon, M.D.

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Dec 6, 2023, 9:00 AM EST - 2 years ago

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Nov 2, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

Sep 26, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

Sep 7, 2023, 9:00 AM EDT - 3 years ago

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Jul 19, 2023, 9:00 AM EDT - 3 years ago

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Jul 13, 2023, 9:00 AM EDT - 3 years ago

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

Mar 7, 2023, 9:00 AM EST - 3 years ago

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Dec 16, 2022, 9:00 AM EST - 3 years ago

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Synaptogenix Announces $15 Million Private Placement with Existing Investors

Nov 18, 2022, 9:00 AM EST - 3 years ago

Synaptogenix Announces $15 Million Private Placement with Existing Investors

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Oct 19, 2022, 9:00 AM EDT - 3 years ago

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

Sep 28, 2022, 11:50 AM EDT - 3 years ago

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

Aug 12, 2022, 9:00 AM EDT - 4 years ago

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

Jul 26, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

Synaptogenix Announces Corporate Update Conference Call

Jul 21, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix Announces Corporate Update Conference Call

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Jul 20, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Synaptogenix to Present at the Cell Symposium

May 17, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present at the Cell Symposium

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

Apr 19, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease

Apr 5, 2022, 9:15 AM EDT - 4 years ago

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Mar 29, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Mar 22, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Mar 15, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Feb 23, 2022, 9:15 AM EST - 4 years ago

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

Feb 1, 2022, 9:15 AM EST - 4 years ago

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference

Sep 10, 2021, 9:00 AM EDT - 5 years ago

Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference

Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome

Aug 5, 2021, 10:00 AM EDT - 5 years ago

Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome

Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021

Jul 26, 2021, 9:15 AM EDT - 5 years ago

Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021

EndGame1
EndGame1 Sep. 18 at 2:55 PM
$TAOX Patience paid off. I'm getting close to break even. $5 this month. Bittensor TAO Price #37 rank $252.63 29.4% (1month) "Bittensor saw an 8% price increase following the launch of Subnet 68 (NOVA) for 'Agency Therapeutics' discovery. Increased community engagement and social bullishness also contributed to the upward momentum."
0 · Reply
show_me_the_money_Adam
show_me_the_money_Adam Sep. 18 at 2:03 PM
$TAOX a nice day for crypto!
0 · Reply
EndGame1
EndGame1 Sep. 17 at 3:51 PM
$TAOX We survived that dip. Good days coming. "Bittensor (TAO) rose 3.5% as ORO subnet's Y Combinator acceptance spurred ecosystem development. New cross-chain swaps and app integrations further boosted utility and liquidity, driving positive market sentiment."
0 · Reply
EndGame1
EndGame1 Sep. 14 at 6:15 PM
$TAOX Listening to "This week in Startups" with Jason Calacanis and the founder of $TAO.X explain Bittensor.
0 · Reply
SnoopyPotter
SnoopyPotter Sep. 14 at 5:35 PM
$TAOX Mark Jeffrey is at the All-In Summit with Jason Calacanis and the heavy hitters. Having a Bittensor Fund partner in the room with the people who allocate billions to AI is huge for $TAO.X. This is exactly where decentralized compute needs to be heard. Mindshare + capital conversations in one building. $TAO.X​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​
0 · Reply
EndGame1
EndGame1 Sep. 14 at 4:14 PM
$TAOX Price is flat, but demand is rising. #39 on coin gecko https://www.coingecko.com/en/coins/bittensor?chart=type%3Dprice%26mode%3Dline%26timeframe%3Dd30
0 · Reply
EndGame1
EndGame1 Sep. 8 at 2:53 PM
$TAOX What a Monday. Bittensor $257.30 5.2% bittensor (TAO) 7d chart "Bittensor Surges 25% to $277 on Raydium Listing and Short Squeeze Bittensor's price rose 25% to $277 following its listing on Raydium, strong demand for "Buttensor" trading pairs, and a short squeeze triggered by a concentrated 79% short liquidation position. Protocol upgrades and increased social engagement further supported the rally."
0 · Reply
EndGame1
EndGame1 Sep. 8 at 1:36 PM
$TAOX Should be $5/share. Bittensor is finally found.
0 · Reply
SnoopyPotter
SnoopyPotter Sep. 8 at 12:38 PM
$TAOX I bought some buttensor. as abe experiment - Crashed 75% - gain about $1 in Tao a day off $140 investment - Expecting some more volatility -
1 · Reply
SnoopyPotter
SnoopyPotter Sep. 7 at 2:00 AM
$TAOX Buttensor tao as explained by mark jeffrey : So this morning a 'Bittensor memecoin' appeared on Solana called 'Buttensor' (har har). It was launched in a Raydium pool opposite $TAO.X on Solana. Hold $BUTT.X and you earn $TAO.X. This drives both $BUTT.X and $TAO.X price -- and (important) ALL of this drives **new money** on Solana into TAO either directly or obliquely through BUTT. Through your memecoin antics, Solana people, you drive up the price of serious-coin TAO. The stage is now set for these new kind of price dynamics on both Solana AND Robinhood.
0 · Reply
EndGame1
EndGame1 Sep. 6 at 9:24 PM
$TAOX Don’t look now, but $TAO.X is $269.
1 · Reply
EndGame1
EndGame1 Sep. 3 at 3:22 PM
$TAOX "Bittensor Rises 2.6% on Growing Subnet Activity and Upcoming Exploit Summit Bittensor price increased 2.6% over the past 24 hours as news emerged about growing subnet adoption, including Compelle gaining traction and Sentios providing audits for Mentat Lend. Upcoming Bittensor Exploit Summit in Montreal on September 28–29 will feature live adversarial demos from dozens of subnet teams, boosting network visibility and developer engagement."
0 · Reply
EndGame1
EndGame1 Sep. 3 at 1:53 PM
$TAOX Show me $5 and the long wait will be worth it. $TAO.X Bittensor is making positive changes daily.
0 · Reply
show_me_the_money_Adam
show_me_the_money_Adam Aug. 31 at 7:37 PM
$TAOX Still holding nicely!
0 · Reply
EndGame1
EndGame1 Aug. 29 at 2:59 AM
$TAOX Oh well... "Bittensor Drops 6.9% Amid $5.94M Token Unlock and AI Hype Recession Bittensor's price declined 6.9% over the past 24 hours to $236.41 following a reported $5.94M token unlock, which may have triggered short-term sell pressure. Despite ongoing ecosystem developments and endorsements, the unlock event aligns with the downward price movement."
0 · Reply
EndGame1
EndGame1 Aug. 28 at 1:18 PM
$TAOX "Bittensor Reframed as AI Infrastructure Token Amid Stake-for-Compute Proposals Analysts reframe Bittensor (TAO) as an AI infrastructure token. Proposals like "Conviction Lock" aim to link staked TAO to GPU compute access, potentially boosting demand for locked TAO."
0 · Reply
EndGame1
EndGame1 Aug. 28 at 1:15 AM
$TAOX "Bittensor Jumps 8% Following HTX Listing and Technical Breakout Confirmation Bittensor (TAO) saw an 8% price increase driven by its listing on HTX, increased staking activity, and confirmation of a technical breakout. HTX's listing boosted liquidity, while strong network participation and positive chart signals contributed to the upward momentum."
0 · Reply
EndGame1
EndGame1 Aug. 27 at 11:33 PM
$TAOX Looking good. Congrats to us longs that didn't give up on $TAO.X Bittensor TAO Price #41 $254.54 18.5% (7 day) .
0 · Reply
SnoopyPotter
SnoopyPotter Aug. 27 at 11:10 PM
post from James Altucher : At $TAOX, the largest public holder of $TAO.X tokens, we are super bullish. A) $TAO.X is the largest decentralized AI platform. B) $TAO.X is like an ETF of 128 AI state-of-the-art subnets. C)@const and the other developers on TAO have immense integrity. D) $TAO.X (with 128 valuable companies) has only a $3B market cap vs companies like OpenAI with $1.5Trillion in value. E) $TAO.X is evolving and will become only better with time, through governance and advances in tech. $TAO.X is not a crypto but an AI platform that is succeeding and under-noticed. $TAOX is the public vehicle to invest in TAO. We are invested in $TAO.X , the subnets, and own the largest media outlet about TAO, the @taodaily_io as well as public-facing front-end into TAO inference : http://BlueTAO.ai
1 · Reply
SilentRider1
SilentRider1 Aug. 27 at 10:16 PM
$TAOX
0 · Reply
EndGame1
EndGame1 Aug. 27 at 6:33 PM
$TAOX @ jaltucher X "At $TAOX , the largest public holder of Bittensor tokens, we are super bullish. A) TAO is the largest decentralized AI platform. B) is like an ETF of 128 AI state-of-the-art subnets. C) @ const and the other developers on TAO have immense integrity. D) $TAO.X (with 128 valuable companies) has only a $3B market cap vs companies like OpenAI with $1.5TRILLION in value. E) is evolving and will become only better with time, through governance and advances in tech. TAO is not a crypto but an AI platform that is succeeding and under-noticed. TAO is the public vehicle to invest in TAO. We are invested in TAO, the subnets, and own the largest media outlet about TAO, the @ taodaily_io as well as public-facing front-end into TAO inference : http://BlueTAO.ai
1 · Reply
EndGame1
EndGame1 Aug. 27 at 1:51 PM
$TAOX It's a small company, but every $1 $TAO.X goes up, their coin value goes up $83,000. And that's not counting their Bittensor staking. Bittensor TAO Price $256.59 23.1% (7d)
1 · Reply